Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 17/20 | 0.44 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR6 | P50406 | 1/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | PLA2G5 | P39877 | 1/20 | 0.40 |
| ▸ | PLA2G2E | Q9NZK7 | 1/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6695139 | 0.90 | PLA2G2A (0.51) | PLA2G2APLA2G10 | |
| SCHEMBL818181 | 0.89 | PLA2G2A (0.52) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL29862616 | 0.89 | PLA2G2A (0.52) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6693400 | 0.89 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6693386 | 0.89 | PLA2G2A (0.51) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL6693389 | 0.87 | PLA2G2A (0.54) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL818659 | 0.87 | PLA2G2A (0.43) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E | |
| SCHEMBL29862706 | 0.87 | PLA2G2A (0.41) | PLA2G2APLA2G10DRD2HTR6 | |
| SCHEMBL818305 | 0.87 | PLA2G2A (0.41) | PLA2G2APLA2G10DRD2HTR6 | |
| SCHEMBL3258181 | 0.86 | NPC1 (0.48) | PLA2G2APLA2G10PLA2G1BPLA2G5PLA2G2E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0952149-B1 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | LILLY CO ELI (US) | 2004-06-09 | — | — | EP | disclosed |
| US-6713645-B1 | INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK | ELI LILLY AND COMPANY | 2004-03-30 | — | — | US | disclosed |
| US-6177440-B1 | THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR | ELI LILLY AND COMPANY | 2001-01-23 | — | — | US | disclosed |
| EP-0952149-A2 | Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors | ELI LILLY AND COMPANY (US) | 1999-10-27 | — | — | EP | disclosed |